SE9703929D0 - Therapeutical use and method - Google Patents

Therapeutical use and method

Info

Publication number
SE9703929D0
SE9703929D0 SE9703929A SE9703929A SE9703929D0 SE 9703929 D0 SE9703929 D0 SE 9703929D0 SE 9703929 A SE9703929 A SE 9703929A SE 9703929 A SE9703929 A SE 9703929A SE 9703929 D0 SE9703929 D0 SE 9703929D0
Authority
SE
Sweden
Prior art keywords
therapeutic use
secretagogue compound
acth
medicament
manufacture
Prior art date
Application number
SE9703929A
Other languages
English (en)
Inventor
Ferruccio Berti
Vito De Gennaro Colonna
Eugenio Mueller
Giuseppe Rossoni
Muny Boghen
Magnus Nilsson
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9604300A external-priority patent/SE9604300D0/sv
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9703929A priority Critical patent/SE9703929D0/sv
Publication of SE9703929D0 publication Critical patent/SE9703929D0/sv
Priority to PCT/SE1997/001957 priority patent/WO1998022124A1/en
Priority to AU51424/98A priority patent/AU5142498A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
SE9703929A 1996-11-22 1997-10-28 Therapeutical use and method SE9703929D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9703929A SE9703929D0 (sv) 1996-11-22 1997-10-28 Therapeutical use and method
PCT/SE1997/001957 WO1998022124A1 (en) 1996-11-22 1997-11-21 Use of growth hormone secretagogue compound for treating cardiac failure or related vascular dysfunction
AU51424/98A AU5142498A (en) 1996-11-22 1997-11-21 Use of growth hormone secretagogue compound for treating cardiac failure or related vascular dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604300A SE9604300D0 (sv) 1996-11-22 1996-11-22 Therapeutical use and method
SE9703929A SE9703929D0 (sv) 1996-11-22 1997-10-28 Therapeutical use and method

Publications (1)

Publication Number Publication Date
SE9703929D0 true SE9703929D0 (sv) 1997-10-28

Family

ID=26662804

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703929A SE9703929D0 (sv) 1996-11-22 1997-10-28 Therapeutical use and method

Country Status (3)

Country Link
AU (1) AU5142498A (sv)
SE (1) SE9703929D0 (sv)
WO (1) WO1998022124A1 (sv)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
US6025471A (en) * 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
WO2000030588A2 (en) * 1998-11-26 2000-06-02 Auckland Uniservices Limited Treatment of hypertension
AU2001274601A1 (en) 2000-06-23 2002-01-02 Kaken Pharmaceutical Co., Ltd. Preventives or remedies for heart failure
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
JPWO2004014412A1 (ja) * 2002-08-09 2005-12-02 科研製薬株式会社 心筋細胞保護剤
JP2005539091A (ja) 2002-08-23 2005-12-22 バラリゼーション−ラシェアシェイ ソサイテ エン コマンディテ アテローム性動脈硬化および高コレステロール血症の治療または予防における成長ホルモン放出ペプチド類
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005039625A1 (en) * 2003-10-28 2005-05-06 Rheoscience A/S Growth hormone secretagogue receptor agonists
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
WO2013190520A2 (en) * 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE133073T1 (de) * 1990-10-25 1996-02-15 Genentech Inc Verwendung gegen reaktive sauerstoffverbindungen schützender wirkstoffe

Also Published As

Publication number Publication date
AU5142498A (en) 1998-06-10
WO1998022124A1 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
SE9703929D0 (sv) Therapeutical use and method
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
BG107537A (en) Method for the inhibition of human tnf alpha activity and its application
ATE255635T1 (de) Polypeptid, fähig zur inhibierung der bindung zwischen menschliches il-6 und dessen rezeptor
HU9403052D0 (en) Treatment of macular degradation
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
PL342099A1 (en) Therapeutic agents
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
MX9701187A (es) Nuevas lactamas naftofusionadas n-substituidas.
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
IT1293583B1 (it) Uso dell'acido gammaidrossibutirrico per il trattamento delle sindromi demenziali
EP0835662A3 (en) A drug for the treatment of cancer
DE69218200T2 (de) Behandlung von leberkrebs
NO992985L (no) Anvendelse av COMT inhibitorer for fremstilling av et legemiddel til Õ forhindre diabetisk vaskulµr dysfunksjon
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
CA2237643A1 (en) Therapeutic agent for acute hepatic failure
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
ATE305795T1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie
WO1998046193A3 (en) Synergistic method for treating a neoplasm
DE69133542D1 (de) Katheter zur Behandlung von Prostaterkrankungen
CS846287A1 (en) Aid for vascular prostheses treatment of venous origin
FI890595A0 (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara tiadiazoler.